On April 24, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Call and Webcast Presentation:
Date and Time: Monday, April 27, 2026 at 8:00am ET
Toll Free: 1-877-407-9716
International: 1-201-493-6779
Conference ID: 13760371
Webcast Presentation: View Source;tp_key=efc315f5a6
A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the "Events" page under the Investors section of the Company’s website.
(Press release, Compass Therapeutics, APR 24, 2026, View Source [SID1234664762])